Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Reexamination Certificate
2011-08-09
2011-08-09
Zucker, Paul A (Department: 1621)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
C560S149000
Reexamination Certificate
active
07994218
ABSTRACT:
Pantoic acid ester neopentyl sulfonyl ester prodrugs of acamprosate, pharmaceutical compositions comprising such prodrugs, and methods of using such prodrugs and compositions thereof for treating diseases are disclosed. In particular, acamprosate prodrugs exhibiting enhanced oral bioavailability and methods of using acamprosate prodrugs to treat neurodegenerative disorders, psychotic disorders, mood disorders, anxiety disorders, somatoform disorders, movement disorders, substance abuse disorders, binge eating disorder, cortical spreading depression related disorders, tinnitus, sleeping disorders, multiple sclerosis, and pain are disclosed.
REFERENCES:
patent: 4199601 (1980-04-01), Durlach
patent: 4355043 (1982-10-01), Durlach
patent: 5073641 (1991-12-01), Bundgaard et al.
patent: 5596095 (1997-01-01), Roberts et al.
patent: 5716961 (1998-02-01), Sands
patent: 5952389 (1999-09-01), Fogel
patent: 6265437 (2001-07-01), Berthelon et al.
patent: 6294583 (2001-09-01), Fogel
patent: 6391922 (2002-05-01), Fogel
patent: 6514524 (2003-02-01), Saslawski et al.
patent: 6689816 (2004-02-01), Fogel
patent: 7351740 (2008-04-01), Zerangue et al.
patent: 2002/0013366 (2002-01-01), Fogel
patent: 2002/0119912 (2002-08-01), Fogel
patent: 2003/0158254 (2003-08-01), Zerangue et al.
patent: 2004/0102525 (2004-05-01), Kozachuk
patent: 2005/0148673 (2005-07-01), Harbut et al.
patent: 2006/0063802 (2006-03-01), Guitton et al.
patent: 2006/0128802 (2006-06-01), Fogel
patent: 3019350 (1989-11-01), None
patent: WO 96/18609 (1996-06-01), None
patent: WO 2007/032720 (2007-03-01), None
U.S. Appl. No. 12/204,961, filed Sep. 5, 2008, Jandeleit et al.
U.S. Appl. No. 12/205,031, filed Sep. 5, 2008, Jandeleit et al.
U.S. Appl. No. 12/205,275, filed Sep. 5, 2008, Jandeleit et al.
U.S. Appl. No. 12/225,167, filed Oct. 15, 2008, Jandeleit et al.
Abbott et al., The formalin test: scoring properties of the first and second phases of the pain response in rats.Pain1995, 60, 91-102.
Azevedo and Figueiredo, Tinnitus treatment with acamprosate: a double-blind study.Rev Bras Otorrinolaringol2005, 71(5), 618-23.
Bauer and Brozoski, Assessing tinnitus and prospective tinnitus therapeutics using a psychophysical animal model.J Assoc Res Otolarynology2001, 2(1), 54-64.
Bauer and Brozoski, Effect of gabapentin on the sensation and impact of tinnitus.Laryngoscope2006, 116(5), 675-81.
Bello and Hajnal, Acute methylphenidate treatments reduce sucrose intake in restricted-fed bingeing rats.Brain Res Bulletin2006, 70, 422-29.
Buda-Levin et al., Baclofen reduces fat intake under binge-type conditions.Physiology&Behavior2005, 86, 176-84.
Bundgaard Ed., “Design of prodrugs,” Elsevier Science Publishing, Netherlands, 1985.
Bundgaard in “A Textbook of Drug Design and Development,” Krogsgaard-Larsen and Bundgaard Eds., Harwood Academic, Philadelphia, 1991, pp. 113-192.
Chapman et al., Anticonvulsant activity of two metabotropic glutamate group I antagonists selective for the mGlu5 receptor: 2-methyl-6-(phenylethynyl)-pyridine (MPEP), and (E)-6-methyl-2-styryl-pyridine (SIB 1893).Neuropharmacology2000, 39, 1567-74.
Correll et al., Subanesthetic ketamine infusion therapy: a retrospective analysis of a novel therapeutic approach to complex regional pain syndrome.Pain Med2004, 5(3), 263-75.
Daoust, et al., Acamprosate modulates synaptosomal GABA transmission in chronically alcoholised rats.Pharmacol. Biochem. Behav. 1992, 41, 669-74.
De Azevedo et al., 109thMeeting and OTO EXPO of the Am. Acad. Otolaryngology—Head and Neck Foundation, Los Angeles, CA, Sep. 25-28, 2005.
De Witte et al., Neuroprotective and abstinence-promoting effects of acamprosate—elucidating the mechanism of action.CNS Drugs2005, 19(6), 517-37.
Eisenberg et al., Effect of early administration of the N-methyl-D-aspartate receptor antagonist amantadine on the development of postmastectomy pain syndrome: a prospective pilot study.J Pain2007, 8(3), 223-9.
Fabbrini et al., Levodpa-induced dyskinesias.Movement Disorders2007, 22(10), 1379-1389.
Goetz et al., Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial.Movement Disorders2007, 22(2), 179-86.
Han et al., The effect of acamprosate on alcohol and food craving in patients with alcohol dependence.Drug Alcohol Dependence2008, 93, 279-83.
Heilig and Egli, Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.Pharmacology&Therapeutics2006, 111, 855-76.
Jensen et al., Transient lower esophageal sphincter relaxations in dogs are inhibited by a metabotropic glutamate receptor 5 antagonist.Eur J Pharmacology2005, 519, 154-57.
Johnson and Ait-Daoud, Neuropharmacological treatments for alcoholism: scientific basis and clinical findings.Psychopharmacology2000, 149(4), 327-44.
Kast and Altschuler, Consideration of acamprosate for treatment of amyotrophic lateral sclerosis.Med Hypotheses2007, 69(4), 836-837.
Killestein et al., Glutamate inhibition in MS: the neuroprotective properties of riluzole.J Neurol Sci2005, 233(1-2), 113-15.
Kornhuber and Quack, Cerebrospinal fluid and serum concentrations of the N-methyl-D-aspartate (NMDA) receptor antagonist memantine in man.Neruosci Lett1995, 195(2), 137-39.
Lea and Faden, Metabotropic glutamate receptor subtype 5 antagonists MPEP and MTEP.CNS Drug Rev2006, 12(2), 149-66.
Lipton, Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurological insults.NeuroRx2004, 1(1), 101-10.
Más-Serrano et al., Kinetic study of acamprosate absorption in rat small intestine.Alcohol Alcohol2000, 35(4), 324-30.
Mcgeehan and Olive, Attenuation of cocaine-induced reinstatement of cocaine conditioned place preference by acamprosate.Behav Pharmacol2006, 17(4), 363-7.
Mela et al., Antagonism of metabotropic glutamate receptor type 5 attenuates L-DPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease.J Neurochemistry2007, 101, 483-497.
Menniti et al., CP-101,606, and NR2B subunit selective NMDA receptor antagonist, inhibits NMDA and injury induced c-fos expression and cortical spreading depression in rodents.Neuropharmacology2000, 39, 1147-55.
Molina-Hernandez et al., Antidepressant-like and anxiolytic-like actions of the mGlu5 receptor antagonist MTEP, microinjected into lateral septal nuclei of male Wistar rats.Prog Neuro-Psychopharmacology Biolog Psychiatry2006, 30, 1129-35.
Murman et al., Cognitive, behavioral, and motor effects of the NMDA antagonist ketamine in Huntington's disease.Neurology1997, 49(1), 153-61.
Nozaki-Taguchi et al., Vincristine-induced allodynia in the rat.Pain2001, 93, 69-76.
Overman et al., Acamprosate for the adjunctive treatment of alcohol dependence.Annals Pharmacotherapy. 2003, 37, 1090-99.
Paille et al., Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol.Alcohol Alcohol1995, 30, 239-47.
Papot et al., Design of selectively activated anticancer prodrugs: elimination and cyclization strategies.Curr Med Chem—Anti-Cancer Agents, 2002, 2, 155-85.
Paz et al., Glutamatergic dysfunction in schizophrenia: from basic neuroscience to clinical psychopharmacology.Eur Neuropsychopharmacology2008, prepublication No. NEUPSY-10085, 14 pages.
Peeters et al., Effects of pan- and subtype-selective N-methyl-D-aspartate receptor antagonists on cortical spreading depression in the rat: therapeutic potential for migraine.J Pharmacology and Experimental Therapeutics2007, 321(2), 564-72.
Pelc et al., Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebo-controlled dose-finding study.Br. Psychiatry1997, 171, 73-77.
Pud et al., The NMDA receptor antagonist amantadine reduces surgical neuropathic pain in cancer patients: a double blind, randomized, placebo controlled trial.Pain1998, 75(2-3), 349-54.
Rabben et al., Prolonged analgesic effect of ketamine, an N-methyl-D-aspartate receptor inhibitor, inpatients with chr
Fischer Wolf-Nicolas
Gallop Mark A.
Jandeleit Bernd
Li Yunxiao
Virsik Peter A.
Dorsey & Whitney LLP
XenoPort, Inc.
Zucker Paul A
LandOfFree
Simple pantoic acid ester neopentyl sulfonyl ester... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Simple pantoic acid ester neopentyl sulfonyl ester..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Simple pantoic acid ester neopentyl sulfonyl ester... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2720040